NVS
Stock Details
NVS is Novartis AG's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 86.78$. Average daily volumn in 3 months 2.47M. Market cap 186.65B
Stock symbol : NVS. Exchange : NYSE. Currency : USD Lastest price : 84.36$. Total volume : 1.81M. Market state CLOSED Click reload if you want to check the lastest price on market!!!
Novartis AG (NVS)
Last Price
84.36$Change
-0.17Volume
1.81M
| Previous Close | 84.53 |
| Open | 83.27 |
| Day Range | 83.07-84.37 |
| Bid | 83.99 x 900 |
| Ask | 84.68 x 900 |
| Volume | 1.81M |
| Average Volume | 2.47M |
| Market Cap | 186.65B |
| Beta | 0.48 |
| 52 Week Range | 79.09-95.17 |
| Trailing P/E | 7.88 |
| Foward P/E | 12.44 |
| Dividend (Yield %) | 3.94% |
| Ex-Dividend Date | 2022-03-08 |
Financial Details
Organization
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form me... dicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Market Cap:
186.65BRevenue:
52.88BTotal Assets:
131.79BTotal Cash:
12.41B
News about "Novartis AG"
Fifth Third Bancorp Sells 787 Shares of Novartis AG (NYSE:NVS)
Source from : Defense World - 10 hours ago
Fifth Third Bancorp trimmed its stake in shares of Novartis AG (NYSE:NVS – Get Rating) by 1.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm ...See details»
Wedbush Securities Inc. Trims Holdings in Novartis AG (NYSE:NVS)
Source from : Defense World - 10 hours ago
Wedbush Securities Inc. trimmed its position in shares of Novartis AG (NYSE:NVS – Get Rating) by 4.9% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The ...See details»
Novartis Leaning Toward Spinoff of $25 Billion Generics Arm
Source from : YAHOO!Finance - 2 days ago
Novartis AG is leaning toward a spinoff of its generic-drug unit, as a challenging environment for leveraged buyouts makes a potential sale to private equity more difficult, people familiar with the ...See details»
Novartis weighs listing of $25B generic unit – Bloomberg
Source from : Seeking Alpha - 2 days ago
Swiss drugmaker, Novartis AG (NVS) (NVSEF) is said to be leaning towards a potential spinoff of its Sandoz business and a separate listing of the $25B generics drug unit ...See details»
Novartis (NVS) Announces Positive Data on Oncology Drug
Source from : Nasdaq - 1 days ago
Novartis AG NVS recently announced results from the late-stage RATIONALE 306 study on tislelizumab. Novartis is developing tislelizumab in collaboration with BeiGene BGNE. Novartis has the right to ...See details»
Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study
Source from : YAHOO!Finance - 2 days ago
Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal ...See details»
385 Shares in Novartis AG (NYSE:NVS) Purchased by DeDora Capital Inc.
Source from : ETF Daily News - 5 days ago
DeDora Capital Inc. acquired a new stake in Novartis AG (NYSE:NVS – Get Rating) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 385 shares of ...See details»
Novartis loses in patent appeal over multiple sclerosis drug
Source from : Reuters - 11 days ago
A U.S. appeals court on Tuesday ruled that a patent related to Swiss drugmaker Novartis AG's blockbuster multiple sclerosis drug Gilenya was invalid, potentially paving the way for introduction of a ...See details»
Novartis to cut up to 8,000 jobs globally
Source from : Reuters - 4 days ago
An employee smokes a cigarette beside the logo of Swiss drugmaker Novartis AG in front of a plant in Basel October 25, 2011. REUTERS/Arnd Wiegmann ...See details»
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS
Source from : Associated Press - 8 days ago
Pomerantz LLP is investigating claims on behalf of investors of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS). Such inv ...See details»
Glassy Mountain Advisors Inc. Buys 1,163 Shares of Novartis AG (NYSE:NVS)
Source from : ETF Daily News - 10 days ago
Glassy Mountain Advisors Inc. lifted its stake in Novartis AG (NYSE:NVS – Get Rating) by 3.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor ...See details»
Novartis (NVS) Gets Positive CHMP Opinion for Scemblix in CML
Source from : Nasdaq - 5 days ago
The committee recommended approval to Scemblix for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP), in adult patients who are previously ...See details»
Bragar Eagel & Squire, P.C. Is Investigating Novartis, Medallion, RBB, and Agrify and Encourages Investors to Contact the Firm
Source from : Associated Press - 7 days ago
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Novartis AG (NYSE: NVS), Medallion Financial Corp. (NASDAQ: MFIN), RBB ...See details»
Pearl Huang to lead Novartis-partnered startup
Source from : The Business Journals - 4 days ago
Former Roche and Cygnal Therapeutics executive Pearl Huang is now the CEO and 12th employee of a tiny startup called Dunad Therapeutics.See details»